• Path SpermQT™ is revolutionizing male fertility testing with breakthrough epigenetic technology

  • Path SpermQT™ is an advanced, molecular sperm quality test that goes beyond the standard semen analysis

  • Path SpermQT™ is raising the standard of care for male reproductive health


Male fertility testing hasn’t changed in 50 years

1 in 8 couples experience infertility.¹ 50% of fertility issues can be attributed to male factors.²
Unfortunately, the current standard of care for semen analysis leaves many unanswered questions.
Looking at sperm with a microscope to count motile sperm is not enough.

The New Standard of Care

Path SpermQT is an advanced molecular sperm quality test that is 6x more predictive of pregnancy³ than standard semen analysis.

New information to provide more personalized and effective treatment plans for couples. A better path to pregnancy. 

Our Science

Our Mission

RAISE THE STANDARD. We believe the path to pregnancy is a shared journey that deserves the best that science has to offer. Couples who understand the unique biology of both the egg and the sperm can make more informed plans for their future family. Path Fertility is on a mission to raise the standard of care for male reproductive health.

We work with providers and patients at all stages of the fertility journey 


Learn how Path SpermQT can help guide your treatment plan.


Find out how Path SpermQT can impact your path to pregnancy.

Our Network

“The more you know, the better things will go. Path SpermQT helps my patients know more before their fertility journey.”

Dr. Aimee Eyvazzadeh – Eggwhisperer
Reproductive Endocrinology & Infertility Specialist

“We now have a diagnostic that significantly improves the measurement of sperm quality. Path SpermQT provides the reassurance to move forward with natural or assisted conception.”

Dr. Alex Pastuszak
Male Fertility Specialist


  1. CDC: https://www.cdc.gov/nchs/fastats/infertility.htm; Review article: Luke, Barbara. “Pregnancy and birth outcomes in couples with infertility with and without assisted reproductive technology: with an emphasis on US population-based studies.” American journal of obstetrics and gynecology vol. 217,3 (2017): 270-281. doi:10.1016/j.ajog.2017.03.012

  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691969/

  3. Path SpermQT White Paper

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound
Cart Overview